Porsolt and KWS have entered into a co-marketing agreement to promote a common catalogue of preclinical tests in the area of inflammation and immunology for pharmaceutical and biotechnology companies.
The partnership enables Porsolt and KWS to deliver a complete cascade of tests to evaluate drug candidates, from simple screening assays to more complex models with high translational value.
It is hoped to provide customers with integrated solutions for highly efficient discovery and development of their drug candidates in these therapeutic domains.
